Launch of Major New Businesses
First written in FY2016. 14 of 17 entries say "Advanced", first in FY2017. Latest entry: FY2026.
The whole theme swung hardest in 2020: 2 of 10 companies on the "Worse" side.
8 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Biodegradable Biopolymer Capacity Expansion」
For large-scale new businesses, multiple facility plans are taking concrete shape, including the expansion of Green Planet's capacity to 15,000 tonnes per year, a 3 m³ pilot facility using CO2 as a raw material, and a new catheter plant at Tomatoh in Hokkaido with capacity of 1 million units per year, scheduled for completion in March 2027. - FY2025-H1AdvancedAnnual report
「We will steadily proceed with the launch of the mass-production demonstration plant.」
For Green Planet, the company has indicated a policy of moving from the capacity expansion planning stage to the launch stage of the mass-production demonstration plant. - FY2024-Q3AdvancedAnnual report
「The blood purification device plant in Hokkaido is progressing as planned toward operation this spring. We will steadily bring the planned innovative technologies into operation and continue launching high-value-added products.」
The blood purification device plant in Hokkaido is progressing as planned toward operation this spring, while the company is moving forward with the introduction of innovative technologies and the launch of high-value-added products. - FY2024-Q1AdvancedAnnual report
「Construction to expand mRNA capacity in response to growing customer needs is scheduled for completion at year-end, and high growth is expected in applications for genetic disease and cancer therapies.」
Capacity expansion for mRNA production facilities has progressed to the construction stage, with completion scheduled for year-end in response to growing customer needs. - FY2023AdvancedAnnual report
「At Pharma's Kaneka Eurogentec, the company has decided to expand capacity for mRNA production facilities, which are expected to deliver high growth for gene therapies and cancer therapies in addition to infectious disease vaccines.」
The policy of launching large-scale new businesses has taken concrete form in the decision to expand mRNA production capacity for gene therapies and cancer therapies, in addition to infectious disease vaccines. - FY2023-Q3AdvancedAnnual report
「Kaneka Eurogentec has decided to expand capacity for mRNA production facilities, which are expected to deliver high growth not only for infectious disease vaccines but also for genetic disease and cancer therapies. The company is expanding its business platform for significant growth.」
As one of its large-scale new businesses, the company has decided to expand capacity for mRNA production facilities for genetic disease and cancer therapies, in addition to infectious disease vaccines. - FY2022-Q3AdvancedAnnual report
「① Large-scale capacity expansion for biodegradable polymer (Green Planet) (Investment of approximately ¥15 billion, 15,000 tonnes per year; operation began in January 2024) ② Construction of a new medical device plant in Hokkaido (Investment of approximately ¥10 billion; operation began in May 2024)」
For large-scale new businesses, the company described the capacity expansion for Green Planet and construction of a new medical device plant in Hokkaido as specific capital investment decisions, including investment amounts, capacity and operating schedules. - FY2021ReframedAnnual report
「We will accelerate the commercialization of new businesses. We will select and concentrate on themes with sufficient scale and improve R&D productivity.」
The policy of launching large-scale new businesses has been reframed as a management initiative emphasizing selection and concentration on themes with sufficient scale and accelerated commercialization. - FY2021-Q1AdvancedAnnual report
「Application development for epoxy masterbatch has progressed, and the capacity expansion facilities at Takasago began operation as scheduled.」
For epoxy masterbatch, progress has reached the stage at which the capacity expansion facilities began operation as scheduled. - FY2020-Q3AdvancedAnnual report
「To meet strong demand exceeding existing production capacity, we are promptly increasing output through debottlenecking while pushing ahead with capacity expansion work to double capacity for operation in July this year.」
For epoxy masterbatch, demand has exceeded production capacity, and the company is moving forward with increased output through debottlenecking and capacity doubling work scheduled to begin operation in July this year. - FY2020-Q1AdvancedAnnual report
「Adoption of epoxy masterbatch for structural adhesives for automobiles is progressing, and capacity expansion work is under way to meet strong demand. We are also constructing integrated production facilities covering the process from resin to prepreg to further accelerate the development of our composite materials business for the aircraft and space industries, and progress toward the launch is proceeding steadily.」
Capacity expansion work for automotive epoxy masterbatch and construction of integrated production facilities for composite materials for the aircraft and space industries are progressing, and the projects have reached the stage leading toward launch. - FY2019AdvancedAnnual report
「Adoption of epoxy masterbatch for structural adhesives for automobiles is progressing, and we have decided to expand capacity. We are also constructing integrated production facilities covering the process from resin to prepreg to further accelerate the development of our composite materials business for the aircraft and space industries.」
The company decided to expand capacity for epoxy masterbatch for automobiles and is moving toward construction of integrated production facilities covering the process from resin to prepreg for composite materials for the aircraft and space industries. - FY2019-Q2AdvancedAnnual report
「We will develop the business rapidly, using prepreg for which new production facilities have been established as next-generation advanced technology material for the aircraft and space industries.」
For composite materials for the aircraft and space industries, the company is moving toward business development using prepreg following the completion of new production facilities. - FY2019-Q1AdvancedAnnual report
「We will also focus on rapidly developing the business involving composite materials for the aircraft and space industries as next-generation advanced technology materials by constructing new prepreg production facilities.」
For high-performance materials in the aerospace sector, the company described the specific means of business development through the construction of new prepreg production facilities. - FY2018-Q3RestatedAnnual report
「In the aerospace sector, where growth is expected going forward, we will develop new high-performance materials and provide valuable solutions.」
The company has identified the development of high-performance materials and provision of solutions in the aerospace sector as new growth areas. This is presented as a concrete implementation of the existing policy of launching large-scale new businesses. - FY2017AdvancedAnnual report
「We have also developed a new technology for the mass cultivation of human iPS cells.」
In connection with new businesses such as regenerative and cellular medicine, the company described the specific research and development achievement of technology for the mass cultivation of human iPS cells. - FY2016First statedAnnual report
「We will focus on launching large-scale new businesses, including organic EL lighting, biopolymers, optoelectrochemicals, regenerative and cellular medicine, and biopharmaceuticals, and will increase sales of new products.」
The company listed multiple large-scale new businesses and plans to launch them and increase sales of new products.